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Context: Ovarian dysfunction is classically categorized on the basis of cycle history, FSH, and es-
tradiol levels. Novel ovarian markers may provide a more direct insight into follicular quantity in
hypergonadotropic women.
Objective:Theobjectiveofthestudywasto investigatethedistributionofnovelovarianmarkers inyoung
hypergonadotropic women as comparedwith normogonadotropic regularly menstruatingwomen.
Design: This was a nationwide prospective cohort study.
Setting: The study was conducted at 10 hospitals in The Netherlands.
Patients:Women below age 40 yr with regular menses and normal FSH (controls; n 83), regular
menstrual cycles and elevated FSH [incipient ovarian failure (IOF); n  68]; oligomenorrhea and
elevated FSH [referred to as transitional ovarian failure (TOF); n  79]; or at least 4 months am-
enorrhea togetherwith FSH levels exceeding 40 IU/liter [premature ovarian failure (POF); n 112].
Main Outcome Measures: Serum levels of anti-Mu¨llerian hormone (AMH), inhibin B, and antral
follicle count (AFC) was measured.
Results: All POF patients showed AMH levels below the fifth percentile (p5) of normoovulatory
women.NormalAMH levels (p5) could be identified in 75%of IOF, 33%of TOFpatients, and 98%
of controls. AFC and AMH levels changed with increasing age (P 0.0001), whereas inhibin B did
not (P  0.26). AMH levels were significantly different between TOF and IOF over the entire age
range, whereas AFC became similar for TOF and IOF at higher ages.
Conclusions: Compared with inhibin B and AFC, AMH was more consistently correlated with the
clinical degreeof folliclepooldepletion inyoungwomenpresentingwithelevatedFSH levels.AMH
may provide amore accurate assessment of the follicle pool in young hypergonadotropic patients,
especially in the clinically challenging subgroups of patientswith elevated FSH and regularmenses
(i.e. IOF) and inhypergonadotropicwomenwith cycledisturbancesnot fulfilling thePOFdiagnostic
criteria (i.e. TOF). (J Clin Endocrinol Metab 94: 786–792, 2009)
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Abnormal ovarian function is classified into three differentsubgroups, according to the World Health Organization
(WHO). This classification is primarily based on serum levels of
FSH and estradiol (1). FSH levels are regulated through negative
feedback actions of inhibin and estradiol, produced by the ovar-
ian follicles (2). A hypogonadotropic condition (WHO I) indi-
cates disturbance at the hypothalamic-pituitary level, whereas a
normogonadotropic oligo- or amenorrheic state (WHO II) is
associatedwith a pituitary-ovarian dysbalance (3). In contrast, a
hypergonadotropic status (WHOIII) coincideswithovariandys-
function due to follicle pool exhaustion (4).
Idiopathic premature ovarian failure (POF) represents themost
extremephenotypeofdiminishedovarianreserveatyoungage.The
most frequently applied definition of POF is the spontaneous ab-
senceofmensesforat least4months incombinationwithFSHlevels
exceeding 40 IU/liter before age 40 yr. This condition occurs in
approximately 1% of the female population (5). It is not clear,
however, how women below the age of 40 yr with cycle distur-
bancesandahypergonadotropichormonal statuswhodonot fulfill
the strict definition of POF should be counseled with regard to
fertility treatmentnorwhether theyhavea similarovarian follicular
status as POFpatients. In the current study, this intermediate group
is referred to as transitional ovarian failure (TOF).
Incipient ovarian failure (IOF) or late reproductive aging
(stage 3) according to the Stages of Reproductive Aging Work-
shop classification, represents another subgroup characterized
by elevated follicular phase FSH levels alongwith a regularmen-
strual cycle (6). IOF precedes the onset of cycle irregularity and
hence the menopausal transition by 3–10 yr and may be consid-
eredanearly signof advancedovarianaging inyoungwomen (7).
Thorough insight into the ovarian reserve profile of this heter-
ogeneous and clinically important group is still lacking (8).
InWestern society,womenare delaying starting a family until
later in life. As a result, the number of female patients presenting
with elevated FSH levels suggestive of reduced ovarian reserve,
with orwithout cycle abnormalities, is increasing (9). Therefore,
a more thorough insight into the ovarian phenotype of these
patients is warranted. Numerous studies indicate that FSH itself
cannotbeusedas apredictivemarker fordeciding to start infertility
treatment or for ovarian response prediction (10). Recently more
direct ovarian markers, such as anti-Mu¨llerian hormone (AMH),
inhibin B, and antral follicle count (AFC) have become available.
AMH is a product of the granulosa cells that envelop the
oocyte and continues to be expressed until the antral stage (11).
Inhibin B is produced by the cohort of developing preantral and
early antral follicles, and its circulating concentrations are max-
imal during the early tomidfollicular phase (12). Early follicular
inhibin B levels decrease during reproductive aging leading to
increasing FSH concentrations (13). Similarly, AFC decreases
during reproductive aging in line with the contention that the
numberof visible antral follicles reflects the sizeof theprimordial
follicle pool (14). In contrast to FSH, estradiol, inhibin B, and
AFC, AMH levels do not appear to vary with cycle day (15).
Moreover, AMH has a superior cycle-to-cycle reproducibility
compared with inhibin B and FSH (16). AMH levels show a
decreasing trend with age, remaining relatively stable until age
30 yr but declining more steeply thereafter (17, 18).
Scant information exists with regard to AMH levels in pa-
tients presentingwith a hypergonadotropic hormonal status at a
young age. An earlier study compared patients with secondary
amenorrhea with controls and identified a high percentage of
very low or undetectable AMH levels in POF patients (19). An-
other small study identified low AMH levels as marker of di-
minished ovarian reserve in IOF patients with consistently ele-
vated FSH levels (20). The present study aimed to show the
relationship between several direct markers of ovarian reserve
and varying clinical degrees of ovarian failure based on FSH
values and cycle disturbances in women under forty.
Subjects and Methods
Subjects
From October 2004 onward, a nationwide standardized systematic
screening protocol was applied for women with suspected diminished
ovarian reserve visiting the infertility outpatient clinics of 10 Dutch hos-
pitals. This protocol was approved by all local institutional review
boards, and written informed consent was obtained from all participat-
ing women for standardized screening. This screening included a ques-
tionnaire regarding fertility, family history, and climacteric complaints
as well as transvaginal ultrasonography and blood withdrawal.
Inclusion criteria for screening were age between 25 and40 yr, in-
creased FSH serum levels (10.2 IU/liter), a history of having experi-
enced regular menstrual cycles (26–32 d), known last spontaneousmen-
struation date, no current use of hormone therapy, and no history of
radiotherapy/chemotherapy or ovarian surgery. Women with regular
cycles applying to these criteriawere screened in the early follicular phase
(cycle d 2–5), whereas women without a regular cycle were screened at
random and progesterone levels weremeasured additionally. Serumwas
frozen in20 C within 4 h for further analysis. Increased baseline FSH
was defined as greater than 10.2 IU/liter, which is the upper 95% ref-
erence value of the FSHassayused in theUMCUtrecht (ADVIACentaur/
Bayer Corp., Tarrytown, NY). This arbitrary cutoff was chosen because
this assaywasused in the control cohort, and second, aDutch studyusing
another assay identified an upper value of 11.2 IU/liter in regularly men-
struatingwomenbelowage35yr (21); conversion to theADVIACentaur
assay led to a cut-off of 10.4 IU/liter.
IOF was defined as regular cycles between 25 and 35 d with elevated
FSH on cycle d 2–5. TOF patients had (a history of) transformation to
irregular cycles (35 d) with FSH levels exceeding 10.2 IU/liter without
fulfilling the POF criteria. POF was defined as at least one episode of
secondary amenorrhea for more than 120 d (4 months) in combination
with FSH greater than 40 IU/liter.
Proven fertile, regularly menstruating women from an earlier described
cohort served as controls (18). Women with early follicular FSH levels less
than 10.2 IU/liter between 25 and 40 yrwere selected for the current study.
Methods
All serummeasurements in the hypergonadotropic patientswere per-
formed in the same laboratory using the same assays in a single run. FSH
levels were measured using a chemoluminescence-based immunometric
assay (Immulite 2000;Diagnostic ProductsCorp., LosAngeles,CA).The
detection limit of the assay was 0.1 IU/liter, inter- and intraassay coef-
ficients of variation were less than 3.0 and 5.6%. Progesterone was
measured on an ADVIA Centaur immunoassay system (Bayer Corp.,
Tarrytown,NY). Interassay coefficientswere 11, 6, and 5%at 6, 30, and
95 nmol/liter, respectively. Within-run variation for values greater than
10 nmol/liter was less than 3%, and at 5 nmol/liter it was 7%. Luteal
progesterone was set at a value greater than 10 nmol/liter (which coin-
cides with the 2.5th percentile in 84 normoovulatory subjects). Levels of
inhibin B were measured using enzyme immunometric kits (Oxford
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BioInnovation (Oxford, UK). Inter- and intraassay coefficients of vari-
ationwere less than 7.0 and 14%at 240 ng/liter. The detection limit was
10 ng/liter. AMH levels were determined using the enzyme immunomet-
ric assay (Diagnostic Systems Laboratories, Webster, TX). Inter- and
intraassay coefficients of variation were less than 5% at the level of 3
g/liter and less than 11% at the level of 13 g/liter. The detection limit
of the assay was 0.026 g/liter. In controls AMH levels were measured
using the Immunotech Coulter (Marseilles, France) enzyme immuno-
metric assay and converted to Diagnostic Systems Laboratories assay
values as described earlier (15).
AFC was defined as the total number of visible round or oval, intrao-
variantransonicstructureswithdiameterbetween2and10mm.Ultrasound
examinations were performed by experienced fertility specialists in each of
the participating centers. If one or both ovaries could not be visualized, the
AFC was marked as not visible. Low AFC cutoff was set at less than five
follicles because this number is associated with poor response and signifi-
cantly lower rate of pregnancies in in vitro fertilization (IVF) (22). The
menopausal threshold for serum parameters were set as inhibin B less than
10ng/liter (23) andAMHless than0.086g/ml (24). Furthermore, lowered
premenopausalAMHcutoffsweredefinedas less than the fifthpercentile of
the distribution within the normal population by age. This is for age 30
(0.3085 g/ml); 35 (0.2365 g/ml) and 40 [0.1036 g/ml, respectively;
extracted from the original data of Ref. 24)].
Statistics
Continuousvariableswere expressedasmean SDandcategorical vari-
ables as percentages. The ovarian reserve markers were logarithmically
transformed in case of significant deviation from the normal distribution.
This applied to AMH and inhibin B. Therefore, results for these ovarian
markers were presented as medians and range. Between-group differences
were tested with ANOVA for continuous parameters and 2 tests for cat-
egorical parameters, respectively. To assess a systematic changewhenmov-
ing from controls via IOF andTOF to POF, tests for linear trendwere used.
A separate analysiswasperformed to analyze the relationshipbetween each
ovarian reserve parameter and age: multiple linear regression was carried
out with the ovarian reserve parameter as dependent and age and group as
independentvariable.Absolutedifferencesbetweengroupswereassessedas
well as in the interaction between group and age, defined by the slope of the
regression line were tested.
Results
Up to January 2007, a total of 408 patients between 25 and 40
yr with idiopathic elevated FSH visited one of the participating
clinics. For this study62currenthormonal therapyusers, 34with
unknown or unreliable last menses, and 25 patients with a reg-
ular cycle who were not screened in the early follicular phase
were excluded. Additionally, 28 samples were excluded because
of insufficient amount or quality of serum for analysis. In total
342women (68 IOF, 79TOF, 112POFpatients and83 controls)
were included for the current study.
In Table 1 baseline and cycle characteristics at time of screening
are outlined. No statistically significant differences existed in age
(P0.11),bodymass index(P0.38),ageatmenarche(P0.36),
andpack-yearsof smoking (P0.86)betweencontrols, IOF,TOF,
and POF cases. Significant differences (P 0.001) were identified
inmenopausal complaints (flushes and night sweats). By definition
all control and IOF patients had experienced a spontaneous men-
struationwithin theprevious35d,andthiswasalso thecase in65%
of the TOF patients. Thirty-one percent of the POF patients had
experienced a spontaneous bleedwithin the last 4months. In 11%
ofPOFpatients, a secondFSHmeasurement after diagnosis didnot
show an FSH level above 40 IU/liter (Fig. 1).
Endocrine screening (Table 2) identified luteal progesterone
in 12 and 3% of TOF and POF patients, respectively. All mea-
sured mean or median ovarian reserve parameters (FSH, AMH,
inhibin B, and AFC) differed between regular menstruating con-
trols and the hypergonadotropicwomen (P 0.001). AMHwas
detectable in 6% of the POF; all had AMH levels below the fifth
percentile (p5) for their age (Fig. 2).Median AMH value for IOF
was 0.33 g/ml and 0.02 g/ml for TOF. Of the IOF patients
75% had AMH levels in the normal range (P5 for her age)
compared with 33% in the TOF group.
When comparing the direct ovarian parameters inhibin B,
AFC, and AMH (Fig. 3), the slope of the regression lines against
age were significant (P 0.0001) for AFC andAMH, indicating
age dependency. In contrast, inhibin B levels were not signifi-
cantly associated with age (P 0.26) (Fig. 3). When comparing
the regression lines by age for IOF and TOF, AFC failed to dif-
ferentiate between these groups in the higher age groups,
whereas discrimination between these two groups on the basis of
AMH levels was possible at every age group: the difference be-
came more pronounced at advanced age (Fig. 3).
Discussion
The current study describes the direct ovarian reserve markers
AMH, inhibin B, and AFC in young women presenting with
TABLE 1. Baseline characteristics (mean  SD or percentages) of control women and hypergonadotropic patients
Controls (n  83) IOF (n  68) TOF (n  79) POF (n  112)
Age (yr) 34.2  3.4 35.2  3.1 34.0  3.9 35.0  3.7
BMI (kg/m2) 24.6  4.3 24.2  4.7 25.4  6.2 24.3  4.2
Pack-years of smoking 4.2  6.4 3.4  6.0 3.9  5.6 4.1  6.2
Age at menarche (yr) 13.2  1.6 12.9  1.4 12.8  1.7 13.1  1.4
Flushes (percent of patients)a 2 8 40 71
Night sweats (percent of patients)a 0 14 20 51
Cycle history characteristics at time of screening
Last menses 35 d (percent of patients) 100 100 65 10
Last menses 35–120 d (percent of patients) 0 0 22 21
Last menses 120 d (percent of patients) 0 0 14 69
BMI, Body mass index.
a Significantly (P  0.001) different between all subgroups.
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various degrees of hypergonadotropic ovarian failure. Although
ovarian reserve is notwell defined in the literature andno clinical
endpoints such as successful IVF treatment and/or ongoingpreg-
nancy are used in the current descriptive study, our data support
the application of AMH in estimating the extent of follicle pool
depletion in young hypergonadotropic women.
AMH is already a proven ovarian marker with regard to re-
production in nonhypergonadotropic subjects (25). In regular
TABLE 2. Endocrine and ultrasonographic assessment at screening (means  SD)
Controls (n  83) IOF (n  68) TOF (n  79) POF (n  112)
FSH in study batch (IU/liter) N/Aa 14.0  7.8 29.0  30.1 94.6  44.7
Normal (10.2 IU/liter), % N/Aa 28 8 1
FSH 10.2 IU/liter, % N/Aa 72 92 99
FSH 40 IU/liter, % N/Aa 2 19 89
Luteal progesterone, % N/Aa N/A 12 3
Ovarian reserve parameters
AMH (g/ml)b 3.51 (0.09–15.84) 0.33 (0.02–3.56) 0.02 (0.02–4.49) 0.02 (0.02–0.18)
Less than p5 for her age, % 2 25 66 100
Less than P5 at age 30 yr (0.3085), % 5 41 73 100
Less than P5 at age 35 yr (0.2365), % 4 24 66 100
Less than P5 at age 40 yr (0.1036), % 1 13 60 99
Less than mp threshold (0.086), % 0 13 58 99
Undetectable, %c 0 7 52 94
Inhibin B (ng/liter)b 93 (7–249) 85 (7–237) 17 (7–293) 11 (7–110)
Undetectable, %c 2 6 37 44
AFC (no. of follicles in two ovaries) 8.6  5.7 4.4  3.4 5.2  6.8 1.2  2.0
AFC 5, % 24 63 63 91
Zero follicles, % 1 7 21 37
Not visible, % 0 13 23 37
mp, Menopausal; N/A, not applicable.
a In controls no second FSH measurement was performed because this group was selected on FSH level; mean FSH  SD in controls was 6.3  1.7 IU/liter.
b AMH and inhibin B values were logarithmically transformed; therefore, medians and ranges are presented.
c Undetectable levels are less than 0.026 g/ml for AMH and less than 7 ng/liter for inhibin B.
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FIG. 1. FSH (second measurement after diagnosis) and AMH levels (log scale) in relation to age in 112 POF patients; the lines indicate the cutoff value of 40 IU/liter for
FSH and the menopausal threshold (0.086 g/ml) for AMH (24).
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menstruating women, AMH appears to be more predictive of
IVF outcome than other direct ovarianmarkers such as estradiol
and inhibin B (26). Decreased AMH levels are clearly correlated
to poor response in IVF, which is a functional outcome of di-
minished ovarian reserve (27). AMH has also been presented
recently as ausefulmarker of ovariandysfunctionandprediction
of outcomes of intervention in other clinical conditions such as
normogonadotrophic anovulation (chiefly polycystic ovary syn-
drome) (28), anorexia nervosa (29), or chemotherapy-induced
ovarian damage (30). Furthermore, recent studies suggest that
AMH levels may predict age at menopause, and in women ap-
proaching menopause, extremely low AMH levels are observed
(24, 31). However, it has not yet been established whether data
from the normal menopausal transition may be applied to hy-
pergonadotropic ovarian failure at a much younger age.
Our data in POF patients show that AMH values are conse-
quently below themenopausal threshold and in the vastmajority
even undetectable, despite fluctuations in FSH levels and inci-
dental vaginal bleedings. This finding provides further evidence
for the notion that infertility treatment is of no benefit in these
patients with the exception of oocyte donation. In contrast, in
patients with elevated FSH levels and regular cycles (IOF) or
oligo/amenorrhea (TOF), we found that AMHmay still be nor-
mal, suggesting the presence of a fair amount of follicles. We
therefore suggest that AMH may be applied to identify women
with a less abnormal ovarian reserve (i.e. AMH levels above the
fifthpercentile) and thuspossibly abetter reproductivepotential.
Young IOF and TOF patients present more frequently with nor-
mal AMH levels for their age compared with older patients (P
0.07 andP 0.007, respectively). This observation supports the
clinical finding of a normal response to ovarian stimulation in
some women with elevated FSH levels (32). When using AMH
rather than FSH to differentiate between normal or diminished
ovarian reserve, only a quarter of all IOF and two thirds of TOF
patients would be labeled as abnormal. In other words, in 75%
of IOF and one third of TOF patients normal AMH concentra-
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FIG. 3. Regression lines of inhibin B (log scale), AFC, and AMH (log scale) values by age for subgroups of young hypergonadotropic women. --, Controls; --,
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tionswere observeddespite elevatedFSHand cycle disturbances.
However, before AMH can be applied clinically, longitudinal
follow-up studies should prove the ability of AMH to predict
clinical outcome in young hypergonadotropic patients.
Moreover, our data also suggest thatAMHismore consistent
than inhibin B or AFC as a measure to assess the extent of the
follicle pool in these young hypergonadotropic patients, al-
though the results of the regressionanalysis shouldbe interpreted
with caution given the transverse nature of the data. It is inter-
esting, however, that AFC and AMH, which are both direct
markers of ovarian reserve, differ, particularly between the IOF
and TOF subjects. IOF subjects have lower (and more slowly
falling) antral follicle counts than those with TOF. This finding
may indicate that a milder follicle depletion pattern is present in
IOF patients.
Although inhibin B is known to be decreased in older women
(33) and is significantly decreased in TOF and POF patients, its
capacity to differentiate between controls and IOFwas absent in
our cohort. Inhibin B is probably a mere marker of ovarian ac-
tivity rather than of ovarian reserve. Thismay be due to its direct
relationship with the cohort of growing small antral follicles
after secondary follicle recruitment during the luteofollicular
transition (12). A recent longitudinal study in a general popu-
lation cohort demonstrated inhibin B was less predictive of
menopause in the general population than AMH (34). Finally,
inhibin B levels may also be affected by the waxing and waning
of ovarian function often seen during ovarian aging as well as
throughout the menstrual cycle (20).
Overall, the discriminative power of AFC to differentiate be-
tween various subgroups decreases significantly with increasing
age. Earlier studies have shown strong correlations between
AMH and early follicular phase AFC in the context of ovarian
aging (18). Despite this correlation, AFC may reflect the active
cohort of growing follicles (35) rather than the preantral follicle
pool. Our current observations in hypergonadotropic patients
indicate that ultrasonography is not conclusive in 26% of the
patients because one or both ovaries were not visible.Moreover,
AFC requires state-of-the-art ultrasound machines and experi-
enced ultrasonographists (36).
The arbitrary cutoff value for FSH should also be considered.
Different studies, using different outcomes, have used different
FSH cutoff levels (10). A recent large Dutch multicenter trial
(using different assays) using FSH as continues variable identi-
fied fewer pregnancies with FSH levels exceeding 8 IU/liter (37).
Moreover other factors may be involved in regulating absolute
levels of FSH (21), including FSH receptor polymorphisms (38,
39). Hence, factors different from ovarian reserve may also im-
pact on absolute FSH concentrations.
In conclusion, the current prospective, cross-sectional evalu-
ation of ovarian reserve markers in young hypergonadotropic
women indicates that AMH may represent a useful future
marker to assess the extent of diminished ovarian reserve for a
given patient. Moreover, our data further suggest that the clas-
sical role of serum FSH as the primary determinant for diagnos-
ing premature follicle pool depletion, with POF as its extreme
phenotype, may need to be revised. Before the widespread clin-
ical application of AMH can be recommended, longitudinal fol-
low-up data for the general population are needed (34). It would
be extremely useful to define age-dependent AMH cutoff levels.
Furthermore, studies using AMH as an ovarian reserve marker
for clear clinical outcome measures may improve its predictive
value.
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